Navigation Links
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Date:7/22/2009

KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration (FDA). Schering-Plough is seeking marketing approval from the FDA of the mometasone furoate/formoterol fumarate combination for the maintenance treatment of asthma in patients 12 years of age and older.

Mometasone furoate/formoterol fumarate combines the active ingredients of an inhaled corticosteroid, ASMANEX((R) )(mometasone furoate inhalation powder), with the long-acting beta2-agonist, FORADIL((R)) (formoterol fumarate inhalation powder), administered via a single metered-dose inhaler. Schering-Plough has exclusive worldwide rights for the development and commercialization of the mometasone furoate and formoterol furmarate fixed-dose combination.

"We are pleased to announce the U.S. filing of the fixed-dose combination of mometasone furoate and formoterol fumarate," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "If approved by the FDA, the mometasone fuorate/formoterol combination would represent an important additional treatment option for physicians and their patients and further strengthen Schering-Plough's portfolio of respiratory products."

Combination products containing inhaled corticosteroids and long-acting beta2-agonists are the largest segment of the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) medications, in terms of dollar sales (1). The fixed-dose combination of mometasone furoate and formoterol fumarate for the treatment of asthma in patients younger than 12 years of age and for use in COPD is currently in Phase III development.

Schering-Plough is an innovation-dri
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Features Give Molecular Laboratories Increased Efficiencies and Flexibility ... and is Unique in its Ability to Detect and ... Measure All Known Strains of HIV-1, ... ),has received a supplemental Premarket Approval from the U.S. Food and ...
... Solvay Pharmaceuticals, Inc. and,Wyeth Pharmaceuticals, a division of ... an action letter from the U.S. Food and Drug ... for bifeprunox, an,atypical antipsychotic that was reviewed for the ... stable adult patients. The,Agency stated that the drug was ...
Cached Medicine Technology:Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 2Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 3Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 4Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 5Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 6Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia 2Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia 3
(Date:7/28/2014)... DC (PRWEB) July 28, 2014 As ... many are looking to private exchanges. “Private Exchange ... August 6 webinar from Atlantic Information Services, will provide ... private exchange strategies for the future. , Barbara Gniewek, ... PwC with extensive experience in the private exchange sector ...
(Date:7/28/2014)... According to the Heartburn No More PDF review recently updated ... people get rid of acid reflux naturally. This ... and acid reflux. In addition, inside this book, people will ... for reflux disease. , Vkool informs in its review ... of reflux disease naturally without medications. The book also instructs ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Greta Pontarelli, 63, ... the Masters Champion title at the World Pole Sports Championships ... obstacle for this athlete. She is the only U.S. competitor ... the International Pole Sports Federation (IPSF). Over 150 athletes ranging ... took part in the competition. Pontarelli scored first place in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dr. Alan Xenakis, ... “DOC X MD Funny Feelings.” The new book, DOC ... Feelings in a unique story telling style with humor and ... and motivational. The reader will find answers to those age-old ... running water make people pee? Why do mosquitoes bite some ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... gene determines people’s sensitivity to pain.In the study conducted ... prevented by blocking the expression of that particular gene ... a breakthrough in development of new painkillers. ... them had the genetic variant that protects them from ...
... pills for easier swallowing can be dangerous as the tablet’s ... body and crushing could cause serious side effects. ... said, “People can opt to take drugs in patch, liquid ... 60% of the older people. Studies have revealed that tablets ...
... at National University of Singapore recently by researchers, reported ... edition, to study the tangible benefits of curries commonly ... regular consumption of meals which are accompanied by a ... the brain which is often indelibly associated with aging. ...
... Butler, a pioneering plastic and reconstructive surgeon has been ... ethics committee of the Royal Free Hospital, London to ... ,However the Royal College of Surgeons has called for ... transplantation. ,The surgery promises to transform the lives ...
... Sanofi-Aventis' Accomplia (rimonabant), a new drug for treatment of obesity, ... cardiac problems// in people with diabetes type 2. The research was ... in Europe and south and North America. ,Some of them ... others were treated with a placebo, for a 1 year period. ...
... dengue in the capital Thursday taking the death toll in India ... a considerable// fall in the number of fresh cases. ... days with only 74 cases being reported Wednesday across the country, ... ,Officials said it was easily one of the ...
Cached Medicine News:Health News:Gene determines pain threshold... 2Health News:Spices in curries spruce up aging minds 2Health News:Green Signal given to Full-Face Transplants 2Health News:Green Signal given to Full-Face Transplants 3
Inquire...
... MicroAire Power Assisted Lipoplasty Device uses a 2-mm ... facilitate the movement of the cannula in tissue. ... with more fibrous tissue. That makes the lipoplasty ... will ease your mind to learn that the ...
... 1/3 hp. 0-8 scfm/0-29.8 in.hg.@sea level. Incredibly ... to 4 collection canister systems at one ... changes during the procedure. Standard canister set-up ... filters not included). UL, c-UL and CE ...
... new term being used today to describe the nature ... that may have been used in silicone implants in ... is not new technology cohesive is simply a ... together nature of the gel. All of Mentor silicone ...
Medicine Products: